[Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy].
Randomized study in people · 2017
- What was studied
- 100 patients with L5–S1 vertebrogenic radiculopathy
- Main finding
- An open randomized trial reports greater improvement in pain and disability measures when Neuromultivit was added to basic therapy.
Reported findings and study design
100 L5–S1 radiculopathy patients in an open randomized add-on comparison: Neuromultivit plus basic care versus basic care.
Population or model 100 patients with L5–S1 vertebrogenic radiculopathy
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain/disability scales | Add-on arm favored | p<0.05 |
| Adverse-event spectrum | Described as not significantly different | The abstract nevertheless prints p<0.05; this inconsistency is not resolved |
Neuromultivit is the studied preparation; this is class-level context under Binavit, not direct Binavit efficacy.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Open treatment and background therapy limit attribution. Short-term symptom improvement is not direct proof of nerve regeneration.
- Neuromultivit is not Binavit; formulation, route and co-interventions require separate assessment.
Source details
Journal publication
Indexed citation and abstract checked; complete methods and risk-of-bias appraisal pending.
Sources checked
Citation
Khabirov FA, Khaibullin TI, Granatov EV. [Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Study source ↗ · DOI 10.17116/jnevro201711710138-43 · Bibliography entry · Link to this summary